DDInter826 DDInter604
Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl
Drospirenone is a synthetic progestin commonly found in the popular oral contraceptive, Yaz in combination with [Ethinyl estradiol]. Most recently, it was approved by both Health Canada and the FDA in combination with [Estetrol] as an oral contraceptive therapy.[L33199,L33174] Aside from its contraceptive effects, drospirenone is used with estrogens to control acne and premenstrual dysphoric disorder (PMDD). Drospirenone has been the subject of widespread safety concern due to the possibility of an increased risk of venous thromboembolism associated with its use.[A182543,A182552] In 2012, however, a safety statement by the FDA concluded that the increase in the risk of thromboembolism resulting from the use of drospirenone remains unclear, as studies regarding this risk are conflicting. Some studies have demonstrated a significantly increased risk and some demonstrating no risk of thromboembolic events. In its statement, the FDA has mentioned that increased risk of venous thromboembolism with oral contraceptives such as drospirenone exists but remains lower than the risk of this condition during pregnancy and during the postpartum period, and this should be considered when assessing potential risks of hormonal contraceptive use.
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) resembles {v} (Compound) Drospirenone
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methyltestosterone
Methyltestosterone {u} (Compound) resembles {v} (Compound) Drospirenone
Glipizide {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Drospirenone
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Medrysone
Medrysone {u} (Compound) resembles {v} (Compound) Drospirenone
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hydrocortisone
Hydrocortisone {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Norethisterone
Norethisterone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methyltestosterone
Methyltestosterone {u} (Compound) resembles {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Medroxyprogesterone acetate
Medroxyprogesterone acetate {u} (Compound) resembles {v} (Compound) Flurandrenolide
Flurandrenolide {u} (Compound) resembles {v} (Compound) Drospirenone
Glipizide {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Progesterone
Progesterone {u} (Compound) resembles {v} (Compound) Drospirenone
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Drospirenone (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Drospirenone (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Drospirenone (Compound)
Glipizide (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Drospirenone (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Progesterone and Progesterone (Compound) resembles Medrysone (Compound) and Medrysone (Compound) resembles Drospirenone (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) resembles Flurandrenolide (Compound) and Flurandrenolide (Compound) resembles Drospirenone (Compound)
Glipizide (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Progesterone (Compound) and Progesterone (Compound) resembles Drospirenone (Compound)